Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

(2021) Kevin Litchfield et al.   CELL

Advances in immunotherapy for hepatocellular carcinoma

(2021) Bruno Sangro et al.   Nature Reviews Gastroenterology & Hepatology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

(2021) Bryan J. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

(2021) Thomas Yau et al.   LANCET ONCOLOGY

Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase

(2020) Olivier Vollmer et al.   AUTOIMMUNITY REVIEWS

Single-cell genomic approaches for developing the next generation of immunotherapies

(2020) Ido Yofe et al.   NATURE MEDICINE

CellPhoneDB: inferring cell–cell communication from combined expression of multi-subunit ligand–receptor complexes

(2020) Mirjana Efremova et al.   Nature Protocols

The Extended Polydimensional Immunome Characterization (EPIC) web-based reference and discovery tool for cytometry data

(2020) Joo Guan Yeo et al.   NATURE BIOTECHNOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dendritic Cells and Their Role in Immunotherapy

(2020) Alycia Gardner et al.   Frontiers in Immunology

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

(2020) Bruno Sangro et al.   JOURNAL OF HEPATOLOGY

Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T Cell Response Against Immunosuppressive Tumors

(2019) Miro K Viitala et al.   CLINICAL CANCER RESEARCH

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

(2019) Thomas Yau et al.   JOURNAL OF CLINICAL ONCOLOGY

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

(2019) Elisabeth Perez-Ruiz et al.   NATURE

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages

(2019) Harald Wajant et al.   Frontiers in Cell and Developmental Biology

Role of CXCR3 signaling in response to anti-PD-1 therapy

(2019) Xiao Han et al.   EBioMedicine

Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer

(2019) Lichun Ma et al.   CANCER CELL

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers

(2019) David Tai et al.   Cancers

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

(2018) Jan P. Böttcher et al.   CELL

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

(2018) Rituparna Das et al.   JOURNAL OF CLINICAL INVESTIGATION

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

(2018) Carsten Krieg et al.   NATURE MEDICINE

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer

(2018) Nataly Manjarrez-Orduño et al.   Frontiers in Immunology

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance

(2017) Donnele Daley et al.   NATURE MEDICINE

Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses

(2017) Valerie Chew et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity

(2017) Louise A. Elliott et al.   Frontiers in Immunology

Membrane IL1  Inhibits the Development of Hepatocellular Carcinoma via Promoting T- and NK-cell Activation

(2016) D. Lin et al.   CANCER RESEARCH

Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

(2016) Sumit K. Subudhi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients

(2015) Fan Yan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD4 T cells are required for both development and maintenance of disease in a new mouse model of reversible colitis

(2015) J Brasseit et al.   Mucosal Immunology

Krüppel-like factor 4 regulates macrophage polarization

(2011) Xudong Liao et al.   JOURNAL OF CLINICAL INVESTIGATION

The unexpected role of lymphotoxin β receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development

(2010) M J Wolf et al.   ONCOGENE

Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells

(2008) Clare A. Notley et al.   JOURNAL OF EXPERIMENTAL MEDICINE